CRSP: CRISPR Therapeutics AG insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 6 sales totaling $4.10M in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-19 | Kulkarni Samarth | CEO | $2.38M | |
| 2026-10-14 | George Simeon | Director | $720K | yes |
| 2026-10-14 | Kasinger James R. | Officer | $51K | |
| 2026-10-14 | Kulkarni Samarth | CEO | $202K | |
| 2026-10-06 | Kasinger James R. | Officer | $119K | yes |
| 2026-09-22 | Kasinger James R. | Officer | $626K | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | 13G amendment | ORBIS INVESTMENT MANAGEMENT LTD | 5.60% | SEC | |
| 2026-07-27 | 13G amendment | BlackRock, Inc. | 8.30% | SEC |
Institutional ownership (Q2 2026)
526 institutions reported holding $4.01B of CRISPR Therapeutics AG on Form 13F (494 the quarter before). 75 opened a new position and 47 sold out. Shares held by institutions: -1%.
| Largest holders | Shares | Value |
|---|---|---|
| ARK Investment Management LLC | 9,460,939 | $516.00M |
| BlackRock, Inc. | 8,348,977 | $455.35M |
| Orbis Allan Gray Ltd | 5,449,161 | $297.20M |
| Capital World Investors | 4,749,525 | $259.04M |
| STATE STREET CORP | 4,321,666 | $235.70M |
| GSK plc | 3,220,627 | $175.65M |
| GEODE CAPITAL MANAGEMENT, LLC | 2,509,915 | $136.92M |
| SR One Capital Management, LP | 2,038,763 | $111.19M |
| TWO SIGMA INVESTMENTS, LP | 1,988,621 | $108.46M |
| FMR LLC | 1,908,503 | $104.09M |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.